Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
Namrata Singh, Consultant Pathologist at Metropolis Global Reference Lab., shared a post on LinkedIn about a recent article by Nicole M. Pietras et al., published in National Library of Medicine, adding:
“Beyond Low Platelets: Understanding What Triggers Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia (ITP) is often perceived as simply a condition of low platelet counts, but its causes are far more complex.
Understanding the underlying triggers is essential for accurate diagnosis and effective management.
Common Triggers of ITP
1. Infections: Many cases of ITP are preceded by viral infections. Through a mechanism known as molecular mimicry, antibodies produced against viral antigens may mistakenly attack platelet antigens.
Commonly associated infections include:
- HIV
- Hepatitis C virus (HCV)
- Cytomegalovirus (CMV)
- Varicella-zoster virus (VZV)
2. Autoimmune Disorders Loss of immune tolerance can lead to the production of autoantibodies targeting platelets.
Conditions frequently associated with ITP:
- Systemic Lupus Erythematosus (SLE)
- Antiphospholipid Syndrome (APS)
- Evans Syndrome
- Common Variable Immunodeficiency (CVID)
- Autoimmune Lymphoproliferative Syndrome (ALPS)
- Post-hematopoietic stem cell transplantation
3. Drug-Induced Thrombocytopenia Several medications can trigger immune-mediated platelet destruction.
Important examples include:
- Heparin
- Quinine
- Vancomycin
- Linezolid
- Rifampicin
- Carbamazepine
- Phenytoin
- Sulfonamides
- β-lactam antibiotics
- Trimethoprim-sulfamethoxazole
4. Vaccination-Associated Cases Rarely, ITP has been reported following MMR vaccination, particularly in children.
5. Malignancies Secondary ITP may occur in association with:
- Chronic Lymphocytic Leukemia (CLL)
- Lymphomas
- Adenocarcinomas
6. Endocrine Disorders Autoimmune endocrine diseases such as:
- Hypothyroidism
- Addison’s disease
May occasionally be associated with thrombocytopenia.
Clinical Pearl:
ITP remains a diagnosis of exclusion. Identifying secondary causes is crucial because treating the underlying condition may significantly improve platelet counts and patient outcomes.
When evaluating a patient with isolated thrombocytopenia, always think beyond ‘primary ITP’ and actively search for infections, autoimmune disorders, medications, malignancies, and endocrine diseases.”
Title: Immune Thrombocytopenia
Authors: Nicole M. Pietras, Nagendra Gupta, Angel A. Justiz Vaillant, Anthony L. Pearson-Shaver
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 26, 2026, 05:12Saja Al-Zamili: Dual Antithrombotic Therapy After Ischemic Stroke in Atrial Fibrillation – A Meta-Analysis
-
Sep 26, 2026, 04:58Angelo Cascio Rizzo: Ischemic Stroke Phenotyping in ESUS – Insights from a Real-World Cohort
-
Sep 26, 2026, 03:11Alice Mihai: One Blood Donation, Three Lives Touched
-
Sep 26, 2026, 03:01Jensa Morris: Anticoagulation in Thrombocytopenia and Cancer-Associated Thrombosis
-
Sep 26, 2026, 02:37Alireza Arzhangzadeh: Antithrombotic Strategies in Coronary Artery Aneurysm, Ectasia, and Slow Flow
-
Sep 26, 2026, 02:15Sherif Mahmoud: Updated Guideline for Antithrombotic-Associated Intracranial Hemorrhage
-
Sep 25, 2026, 20:01Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation
-
Sep 25, 2026, 19:56Steven Fein: A History of Blood Clots Doesn’t Mean a Healthy Pregnancy Is Out of Reach
-
Sep 25, 2026, 19:54Pedro Perez: “Provoked” VTE May Not Always Mean the Risk Disappears When the Provoking Event Does